|Home | About | Journals | Submit | Contact Us | Français|
The value of clonidine (`Dixarit') for the prophylaxis of migraine has been assessed by a double blind cross-over trial. A dose of up to 0·15 mg daily was used. No effect on the frequency of the headaches could be detected over and above the 60 per cent reduction observed with a placebo. Severity, assessed subjectively by the patient, when it varied between placebo and clonidine, was less with clonidine (p<0·01). There was also some evidence that headaches lasting more than 12 hours were less common during treatment with the drug.